Tazemetostat
Renal Medullary Carcinoma
Epizyme, Inc.Small moleculePhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Renal Medullary Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Atezolizumab National Cancer Institute (NCI) | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | B |
gw786034 Mayo Clinic | Phase 2 | B |
View all 14 →
Same molecule, other indications
Tazemetostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →